The Argatroban and Tissue-Type Plasminogen Activator Stroke Study: final results of a pilot safety study. 226. Barreto AD, Ford GA, Shen L, Pedroza C, Tyson J, Cai C, Rahbar MH, Grotta JC; on behalf of the ARTSS-2 Investigators. Randomized, mul- ticenter trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke). Stroke. 2017;48:1608 1616. 227. Gioia LC, Kate M, Sivakumar L, Hussain D, Kalashyan H, Buck B, Bussiere M, Jeerakathil T, Shuaib A, Emery D, et al. Early rivaroxaban use after cardioembolic stroke may not result in hemorrhagic trans- formation: a prospective magnetic resonance imaging study. Stroke. 228. Whiteley WN, Adams HP Jr, Bath PM, Berge E, Sandset PM, Dennis M, Murray GD, Wong KS, Sandercock PA. Targeted use of heparin, hepa- rinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials. Lancet Neurol. 2013;12:539 545. doi: 229. Sandercock PA, Counsell C, Kane EJ. Anticoagulants for acute isch- aemic stroke. Cochrane Database Syst Rev. 2015:CD000024. 230. Yi X, Lin J, Wang C, Zhang B, Chi W. Low-molecular-weight heparin is more effective than aspirin in preventing early neurologic deteri- oration and improving six-month outcome. J Stroke Cerebrovasc Dis. 231. Chang TS, Jensen MB. Haemodilution for acute ischaemic stroke. Cochrane Database Syst Rev. 2014:CD000103. 232. Ginsberg MD, Palesch YY, Hill MD, Martin RH, Moy CS, Barsan WG, Waldman BD, Tamariz D, Ryckborst KJ; ALIAS and Neurological Emergencies Treatment Trials (NETT) Investigators. High-dose al- bumin treatment for acute ischaemic stroke (ALIAS) part 2: a ran- domised, double-blind, phase 3, placebo-controlled trial. Lancet Neurol. ALIAS Parts 1 and 2 and NETT Investigators. ALIAS (Albumin in Acute Ischemic Stroke) trials: analysis of the combined data from parts 1 and 2. 234. 